PainReform
PRFX
About: PainReform Ltd is a clinical-stage specialty pharmaceutical company. It is focused on the reformulation of established therapeutics. The company's product PRF-110 is based on the local anesthetic ropivacaine, targeting the post-operative pain relief market. PRF-110 is an oil-based, viscous, clear solution that is deposited directly into the surgical wound bed before closure to provide localized and extended post-operative analgesia.
Employees: 6
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
1,910% more capital invested
Capital invested by funds: $1.45K [Q1] → $29.2K (+$27.8K) [Q2]
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
33% more funds holding
Funds holding: 3 [Q1] → 4 (+1) [Q2]
0.96% more ownership
Funds ownership: 0.04% [Q1] → 0.99% (+0.96%) [Q2]
Financial journalist opinion